. Endogenous vasopressin does not mediate hypoxia-induced anapyrexia in rats. J. Appl. Physiol. 86(2): 469-473, 1999.-The present study was designed to test the hypothesis that arginine vasopressin (AVP) mediates hypoxia-induced anapyrexia. The rectal temperature of awake, unrestrained rats was measured before and after hypoxic hypoxia, AVP-blocker injection, or a combination of the two. Control animals received saline injections of the same volume. Basal body temperature was 36.52 Ϯ 0.29°C. We observed a significant (P Ͻ 0.05) reduction in body temperature of 1.45 Ϯ 0.33°C after hypoxia (7% inspired O 2 ), whereas systemic and central injections of AVP V 1 -and AVP V 2 -receptor blockers caused no change in body temperature. When intravenous injection of AVP blockers was combined with hypoxia, we observed a reduction in body temperature of 1.49 Ϯ 0.41°C (V 1 -receptor blocker) and of 1.30 Ϯ 0.13°C (V 2 -receptor blocker), similar to that obtained by application of hypoxia only. Similar results were observed when the blockers were injected intracerebroventricularly. The data indicate that endogenous AVP does not mediate hypoxiainduced anapyrexia in rats.
IN ORGANISMS ranging from protozoans to mammals, body temperature (T b ) decreases in response to a lack of O 2 (3, 34, 35) . The importance of this response is emphasized by reports that show an increase in survival of the tested species if the subjects are allowed to become hypothermic during hypoxia exposure (12) . Anapyrexia (a regulated decrease in T b ) can be a beneficial response in hypoxic animals, because it reduces O 2 consumption according to the Q 10 effect; produces a leftward shift of the oxyhemoglobin dissociation curve, with the resulting improvement of O 2 loading in the lungs; and decreases ventilation, with the resulting blunting in the energetically costly responses to hypoxia (cf. Ref. 35) . Although this protective response is extremely widespread among taxa, little is known about the mechanisms that mediate hypoxiainduced anapyrexia.
Several candidates have been suggested (see Ref. 35 ) as potential mediators of anapyrexia, among them arginine vasopressin (AVP). In support of this hypothesis are the findings that hypoxia causes an increase in the plasma levels of AVP in mammals (10, 24) and that AVP plays an important role in thermoregulation, being an endogenous antipyretic peptide (6) and playing thermoregulatory actions when injected into the central nervous system or systemically (20, 28) .
However, there is only one published study (7) that evaluated the participation of AVP in hypoxia-induced anapyrexia, in which AVP does not seem to mediate the reduction in T b . In that study, anapyrexia was similar in both Brattleboro rats (which lack AVP-containing cells in the central nervous system) and Long-Evans rats (used as a control) (7) . However, thermoregulation may be aberrant in Brattleboro rats. It is known that the Brattleboro rat does not consistently develop fever in response to intraperitoneal and intracerebroventricular (icv) injections of bacterial pyrogens at doses that produce fever in normal rats (9, 14, 30) . Differences could also exist regarding hypoxia-induced anapyrexia. Clearly there is a need to resolve this issue.
Thus the purpose of the present study was to examine the participation of endogenous AVP in hypoxiainduced anapyrexia by using selective AVP V 1 -and AVP V 2 -receptor blockers in Wistar rats, whose thermoregulatory mechanisms are extensively known.
MATERIALS AND METHODS
Animals. Experiments were performed on adult male Wistar rats that weighed 210-280 g, were housed at controlled temperature (25.2 Ϯ 0.9°C), and were exposed to a daily 12:12-h light-dark cycle. The animals were allowed free access to water and food. Experiments were performed between 10:00 AM and 3:00 PM.
Surgery. Animals were anesthetized with 2,2,2-tribromoethanol (Aldrich, Milwaukee, WI), and a Silastic catheter was implanted through the external jugular vein according to the technique of Arms and Ojeda (1). After surgery, animals were treated with 100,000 units of benzyl-penicillin and were allowed to recover for 4 days before the experiments. During this period, the catheters were flushed daily with heparinized saline.
Rats used for icv administration were also anesthetized with 2,2,2-tribromoethanol and fixed in a stereotaxic frame. A stainless steel guide cannula (0.7-mm OD) was introduced into the third cerebral ventricle (coordinates: A, Ϫ0.4 mm; L, 0 mm; D, 7.8-8.5 mm; Ref. 22) . The displacement of the meniscus in a water manometer assured correct positioning of the cannula in the third ventricle. The cannula was attached to the bone with stainless steel screws and acrylic cement. A tight-fitting stylet was kept inside the guide cannula to prevent occlusion. The surgical procedures were performed over a period of 40 min. Experiments were initiated 1 wk after cannula placement.
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Rats used for arterial blood pressure measurements were also anesthetized with 2,2,2-tribromoethanol (Aldrich), and a polyethylene catheter was implanted into the femoral artery for direct blood pressure recording. The arterial catheter was composed of a segment of PE-10 tubing (4.5 cm) that was heat bonded to a 15-cm long PE-50 catheter. The catheter was filled with 0.3% heparin in sterile saline (150 mM NaCl). The PE-10 segment was introduced into the femoral artery until the tip reached the abdominal aorta. The catheter was secured in position with thread, and the PE-50 segment was passed under the skin to be finally extruded at the dorsal side of the animals. After surgery, animals were also treated with 100,000 U of benzyl-penicillin and were allowed to recover for 2 days before experimentation. During this period, the catheters were flushed daily with heparinized saline.
Determination of the effect of hypoxia exposure on T b . Rats were housed in a plastic chamber (5 liters) ventilated with humidified room air for at least 2 h. After the animals remained calm, control T b was determined by inserting a thermoprobe into the colon. It should be pointed out that, before the experiment, the animals were habituated to temperature measurements, which were performed quickly to avoid any stress-induced elevations in T b . Subsequently, a humidified hypoxic gas mixture of 10, 7, or 5% inspired O 2 (AGA, Brazil) was flushed through the chamber for 30 min, and T b was measured again.
Determination 8, 9 )-vasopressin (a selective V 2 -receptor blocker) 1 h before T b was measured again. V 1 -and V 2 -receptor blockers dissolved in pyrogen-free sterile saline were injected by intravenous (iv) bolus injection at a dose of 10 µg/kg body weight. The dose and the period of time after injection when T b was determined were chosen on the basis of previous studies (17, 18, 21, 26) . The doses of both blockers were the same, because the effective doses of these drugs are 0.49 Ϯ 0.11 nmol/kg for the AVP V 1 -receptor blocker (26) and 0.53 Ϯ 0.07 nmol/kg for the AVP V 2 -receptor blocker (18) . The volume of each injection was 0.2 ml, and the drug was flushed in with 0.3 ml of saline. Control animals received injections of saline (0.5 ml iv).
In the rats that received an icv injection of the AVP blockers (0.5 µg/kg), a 10-µl Hamilton syringe and a dental injection needle (200-µm OD, Missy) were used for the injections. AVP blockers were dissolved in a final volume of 1 µl. Injection was performed over a period of 2 min, and, to avoid reflux, 1 min was allowed to elapse before the injection needle was removed from the guide cannula. The dose and the period of time after injection (1 h) when T b was determined were chosen on the basis of a previous study (33) .
Determination of the combined effects of hypoxia and AVP blockers on T b . The same animal chamber was used for all experiments. After the animals were habituated to the experimental condition (ϳ2 h), control T b was measured, and then experimental rats were treated with AVP blockers dissolved in saline at the dose of 10 µg/kg body weight by intravenous bolus injection or at the dose of 0.5 µg/kg body weight by icv injection 30 min before exposure to hypoxia. Hypoxia (7% O 2 ) was then applied to the animals for 30 min, and T b was measured again. Control animals received an iv (0.5 ml) or an icv (1 µl) injection of saline.
Determination of biological activity of the AVP blockers. The biological activity of the AVP V 1 -receptor blocker was assessed by measurements of heart rate (HR) and mean arterial blood pressure (MAP) in unanesthetized, freely moving rats; measurements were made by using a Narco polygraph (Narcotrace 80) connected to a pressure transducer (model P-10000B, Narco). A recording speed of 0.5 mm paper/s was used to minimize artifacts of blood pressure fluctuation. HR was measured by actual pulse counting at a recording speed of 5 mm paper/s. A 30-min period was initially used to measure stabilized control values of blood pressure and HR. Subsequently, animals were injected (iv) with saline, AVP V 1 -receptor blocker, or AVP V 2 -receptor blocker (10 µg/kg body weight) 1 h before AVP (0.1 µg/kg body weight) iv injection. The volume of each injection was 0.2 ml, and the drug was flushed in with 0.3 ml of saline. MAP and HR were calculated from recordings obtained 1 min after AVP injection.
The biological activity of the AVP V 2 -receptor blocker was assessed by measurements of urinary flow. After they were deprived of food for 14 h, the animals were weighed, and water overloads (5% of body weight, 37°C) were administered by gavage at 0 and 60 min, after which the animals were treated (iv) with AVP (1 µg/kg) combined with saline, or with AVP V 1 -or AVP V 2 -receptor blocker (10 µg/kg); then they were placed in individual metabolic cages without access to water or food. Urine samples were collected 60 min after the injections.
Statistical analysis. All values are reported as means Ϯ SD. Changes in T b were evaluated by ANOVA. The differences between means were assessed by the Tukey-Kramer multiplecomparisons test. When variances among columns were not equal in the different groups, a nonparametric ANOVA was employed, and the difference between means was assessed by Dunn's test (see Fig. 5 ). Alternatively, the effect of the AVP blockers on T b was analyzed by the paired t-test. Values of P Ͻ 0.05 were considered to be significant.
RESULTS
In all experimental protocols, T b ranged from 35.9 to 37.1°C during the control period, and the baseline values of the experimental groups did not differ significantly from those of the saline group. During the experiments the mean chamber temperature was 25.2 Ϯ 0.9°C, and room temperature was 24.3 Ϯ 0.7°C.
Effect of hypoxia on T b . Figure 1 shows the effect of hypoxic hypoxia exposure on T b . When inspired O 2 was Fig. 1 . Effect of hypoxia on body temperature (T b ). Values are expressed as means Ϯ SD; n ϭ 6 rats. Significant difference in mean T b measured before and after hypoxia: * P Ͻ 0.05; ** P Ͻ 0.01, respectively.
reduced from 21% to 10, 7, or 5%, a significant reduction in T b was observed.
Effect of the AVP V 1 -and AVP V 2 -receptor blockers on T b .
No change in T b was observed after the AVP blockers were injected either iv or icv. These data are shown in Table 1 . Figure 2 shows the effect of hypoxia on T b after iv injection of saline, AVP V 1 -, or AVP V 2 -receptor blockers. This effect is reported as the difference between T b before and after hypoxia exposure (⌬T b ). A reduction of 1.49 Ϯ 0.41 and 1.30 Ϯ 0.13°C was observed in the animals treated with the AVP V 1 -and AVP V 2 -receptor blockers, respectively. These values do not differ from those observed in control animals and in animals treated with saline. Fig. 2 , icv injections of saline, AVP V 1 -and AVP V 2 -receptor blockers did not alter the magnitude of hypoxia-induced anapyrexia. These data are plotted in Fig. 3 .
Combined effects of hypoxia and iv injection of AVP blockers on T b .

Combined effects of hypoxia and icv injection of AVP blockers on T b . Like the results shown in
Biological activity of the AVP blockers. Figure 4 shows the effect of iv injection of AVP on MAP and HR after saline, AVP V 1 -, or AVP V 2 -receptor blocker injections iv, presented as the difference between data obtained before and after AVP injection (⌬HR and ⌬MAP). Control values were 110.9 Ϯ 11.9 mmHg and 391.7 Ϯ 21.3 beats/min for MAP and HR, respectively. Injections of the AVP blockers caused no change in MAP or HR. AVP injection caused a significant increase in MAP and a reduction in HR. These effects were significantly smaller (P Ͻ 0.05) in the animals treated with AVP V 1 -receptor blocker compared with those treated with saline. Figure 5 shows the effect of AVP on urinary flow of animals submitted to water overloads. AVP injections caused a significant reduction (P Ͻ 0.05) in urinary flow, and the AVP V 2 -receptor blocker, but not the AVP V 1 -receptor blocker, blunted the effect of AVP.
DISCUSSION
The present study provides evidence that endogenous AVP does not mediate hypoxia-induced anapyrexia in rats, because neither icv nor iv treatment with AVP V 1 -and AVP V 2 -receptor blockers altered hypoxiainduced anapyrexia. Our results also show that endogenous AVP does not play any tonic role in thermoregulation under normothermic conditions.
It has been reported that AVP produces thermoregulatory actions when injected into the central nervous system or injected systemically. AVP injected into the ventral septal area causes antipyresis (6) , and, when injected systemically (28) or into a lateral ventricle (20) , it produces hypothermia, whereas AVP injected into the preoptic area elicits hyperthermia (20) . These data indicate that AVP exerts thermoregulatory actions that are both neuroanatomically and functionally specific. Moreover, Kasting (15) showed that hypertonic saline and hemorrhage, which are potent stimuli of AVP release, cause antipyresis in rats, indicating that endogenous AVP can affect central febrile pathways. However, little is actually known about the participation of endogenous AVP in thermoregulation under normothermic conditions. In the present study, rats treated systemically and centrally with both AVP- Values are means Ϯ SD; n ϭ 6 rats. Control periods show body temperature before treatments, and experimental periods correspond to 1 h after treatment. Treatments caused no change in body temperature. Experiments were performed at 25.2 Ϯ 0.9°C. iv, Intravenous; icv, intracerebroventricular; V 1 , V 2 , arginine vasopressive-receptor blockers. (8, 19) .
Several studies have investigated the biological activity of the AVP receptor blockers used in the present study (17, 18, 21, 26) . In addition, we presently tested the biological activity of the AVP blockers under the same experimental conditions used to determine AVP thermoregulatory effects. AVP is classically known for its vasoconstrictor effect by interacting with the AVP V 1 -receptor subtype present in vascular smooth muscle and for its antidiuretic effect by interacting with the AVP V 2 -receptor subtype present in the distal and collector tubules of the kidneys (17) . These characteristics were used to assess the biological activity of the AVP blockers. We observed that AVP injected iv caused an increase in MAP and a reduction in HR. These responses were blunted when rats were treated with the AVP V 1 -receptor blocker (Fig. 4) . Furthermore, we also observed that AVP caused a significant reduction in urinary flow (antidiuretic effect) that was abolished by treatment with the AVP V 2 -receptor blocker (Fig. 5) . These results indicate that the AVP receptor blockers were active and selective under the experimental conditions used in the present study.
Previous studies have demonstrated that hypoxia per se causes anapyrexia (34, 35) . In addition to causing anapyrexia, hypoxia also decreases O 2 consumption by a regulated inhibition of some of the processes requiring O 2 (11, 25) . It has been pointed out that anapyrexia is a protective response, because rats survive longer if allowed to become hypothermic during hypoxia exposure (35) . Thus, anapyrexia during hypoxia offers protection mainly to O 2 -sensitive tissues, but the mechanisms involved remain unknown.
Candidates such as lactate (23), brain acidification (5), and histamine (13, 35) have been proposed as mediators of hypoxia-induced anapyrexia. Moreover, exclusion of glucose from central sites plays a major role in hypoglycemia-induced anapyrexia (2) . A route that mediates the reduction in T b may be the impairment of oxidative phosphorylation, because icv injection of inhibitors of oxidative phosphorylation, such as azide or cyanide, reduces the preferred T b of toads (4) . It is also known that a lack of O 2 reduces oxidative phosphorylation, with a consequent increase in the intracellular levels of adenosine (35) . Because adenosine reduces T b (32) , it could be a mediator of hypoxiainduced anapyrexia. Furthermore, it is also possible that hypoxia elicits anapyrexia through a direct effect on thermosensitive neurons in the preoptic area of the anterior hypothalamus (29) .
AVP has also been extensively suggested as a mediator of hypoxia-induced anapyrexia. Rationales for this hypothesis are 1) hypoxia increases AVP levels in plasma and cerebrospinal fluid (10, 24) ; 2) AVP injected icv (20) or systemically (28) elicits anapyrexia in rats; 3) water deprivation is known to increase AVP levels in plasma and cerebrospinal fluid in response to increased extracellular tonicity and diminished plasma volume in http://jap.physiology.org/ mammals (31); the toad Bufo marinus selects significantly lower preference temperatures when exposed to dry air (16) , and camels reduce their metabolic rate when hypohydrated (27) ; and 4) Shido et al. (28) demonstrated that peripheral vasopressin-induced anapyrexia is attributed to the suppression of nonshivering thermogenesis, and it is known that hypoxia elicits anapyrexia by inhibiting thermogenesis (35) . However, the present study does not support this hypothesis, because neither icv nor iv treatment with AVP blockers altered the magnitude of the drop in T b after exposure to hypoxia (Figs. 2 and 3) .
